Last Updated: May 10, 2026

NEPTAZANE Drug Patent Profile

Name: NEPTAZANE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Neptazane patents expire, and when can generic versions of Neptazane launch?

Neptazane is a drug marketed by Lederle and is included in one NDA.

The generic ingredient in NEPTAZANE is methazolamide. There are seven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the methazolamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Neptazane

A generic version of NEPTAZANE was approved as methazolamide by ANI PHARMS on June 30^th, 1993.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for NEPTAZANE?
What are the global sales for NEPTAZANE?
What is Average Wholesale Price for NEPTAZANE?

Summary for NEPTAZANE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	4,814
DailyMed Link:	NEPTAZANE at DailyMed

Drug patent expirations by year for NEPTAZANE

Recent Clinical Trials for NEPTAZANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	Phase 3
National Eye Institute (NEI)	Phase 3
University of Colorado, Denver	Phase 1/Phase 2

See all NEPTAZANE clinical trials

US Patents and Regulatory Information for NEPTAZANE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lederle	NEPTAZANE	methazolamide	TABLET;ORAL	011721-002	Nov 25, 1991		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lederle	NEPTAZANE	methazolamide	TABLET;ORAL	011721-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.